국내 정신분열병 환자에서 항정신병약물 장기지속형 주사제의 과거, 현재 및 향후 가능성

Abstract

Long-acting injectable (LAI) antipsychotics were developed to increase adherence rates in patients requiring maintenance therapy for schizophrenia. Although, evidence was established that LAIs reduce the risk of relapse and rehospitalization, they were underused or misguided by physician for bias and reluctance of patients. Prevalent uses of LAIs were hindered as well by a strict health insurance regulation in Korea. Shared decision-making by both patients and clinicians should be promoted to maximize the potential advantage of LAIs. Large clinical studies are required to develop a broader understanding about pros and cons of LAIs. Advanced and newly-developed LAIs are about to be introduced in Korea in near future and are expected to broaden the treatment choice in schizophrenia. LAIs should be considered as a valuable treatment option in facilitating relapse prevention and optimum outcome.